Innovative pediatric immunotherapies for

Real-life Possibilities

About Y-mAbs Therapeutics

Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates—naxitamab and omburtamab—which target tumors that express GD2 and B7-H3, respectively.

Our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. With the right partnerships and collaboration, we envision expanding our capabilities to treat adults—changing the course of cancer care and its outcomes.

Learn more

What's New

Y-mAbs to Announce Second Quarter 2020 Financial and Operating Results on August 6, 2020

Y-mAbs Announces Data to be Presented at 2020 SIOP

Y-mAbs Announces Update on SADA Technology and New Preclinical SADA Construct

Read more

Our Focus

Neuroblastoma: A rare pediatric cancer of the nervous system that usually starts on the glands above the kidney and can spread to the abdomen, spine, chest, neck, or pelvis.

Central Nervous System (CNS)/Leptomeningeal Metastases (LM): This condition occurs when cancer spreads to the membranes lining the brain and spinal cord. This can result from many types of cancer, including neuroblastoma.

Osteosarcoma: A cancer that starts in the bones and often develops around the knee or the upper arm.

Diffuse Intrinsic Pontine Glioma (DIPG): A highly aggressive and difficult-to-treat tumor found at the base of the brain.

Medulloblastoma: A type of cancer that starts in the lowest back part of the brain (the cerebellum). Although rare, it is the most common cancerous brain tumor found in children.

Desmoplastic Small Round Cell Tumor (DSRCT): A rare tumor that is usually located in the abdomen.

Learn more

Our Research
& Development

What is antibody immunotherapy and how can it help?

Antibody immunotherapy is a type of treatment that’s designed to target specific antigens (molecules that stimulate an immune response) in the body and neutralize them. In early and ongoing clinical trials, the antibodies developed by Y-mAbs have shown results that garner continued evaluation.

Learn more

Our Patient
& Family Support

Y-mAbs was founded by Thomas Gad, President and Head of Business Development and Strategy, who is also the father of a high-risk neuroblastoma survivor.

After years of searching for an effective option for neuroblastoma, Gad's daughter received treatment from Memorial Sloan Kettering Cancer Center (MSKCC). Since then, Gad has envisioned helping other patients and families get access to the same products.

Y-mAbs may someday help patients fight cancer with their advanced pipeline of antibody immunotherapies, which are currently being investigated in ongoing clinical trials.

For Medical
Professionals

Pediatric cancer has long been a challenge for the medical profession.  With years of growing knowledge and insights, treatment advancements are being made through research.

Y-mAbs is working to develop targeted approaches to treating rare and challenging pediatric cancers with the hope of extending survival and helping with safety concerns.

For
Investors

Y-mAbs Therapeutics, Inc. (Y-mAbs), is a state-of-the-art, late-stage clinical, global biopharmaceutical company that is focused on the research and development of innovative antibody-based products under investigation using a range of cutting-edge technologies, licensed from one of the largest and most prestigious cancer-care establishments in the world—MSKCC.

With its robust pipeline, Y-mAbs is committed to becoming a world leader in creating pediatric-based oncology treatments.